30
Participants
Start Date
November 10, 2023
Primary Completion Date
October 10, 2026
Study Completion Date
October 10, 2026
Adebrelimab,Fruquintinib
Adebrelimab,Fruquintinib combined with chemotherapy
RECRUITING
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital
OTHER